Kestra Medical Technologies (NASDAQ:KMTS) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Key Points

• Kestra Medical Technologies reported a quarterly EPS of ($0.46), exceeding analysts' expectations of ($0.66) by $0.20.
• The company's stock price increased by 1.2% to $18.40, with a significant trading volume of 458,173 shares.
• Wells Fargo lowered its price target for Kestra Medical Technologies from $28.00 to $27.00, while the stock maintains a consensus rating of "Moderate Buy".

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.20, Zacks reports. The company had revenue of $19.37 million during the quarter, compared to the consensus estimate of $17.68 million. Kestra Medical Technologies updated its FY 2026 guidance to EPS.

Kestra Medical Technologies Stock Up 2.3%

Kestra Medical Technologies stock traded up $0.52 during midday trading on Tuesday, hitting $23.20. 548,447 shares of the stock were exchanged, compared to its average volume of 287,231. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $26.15. The stock's 50-day simple moving average is $16.76. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.72 and a current ratio of 6.84.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund bought a new stake in Kestra Medical Technologies in the second quarter worth about $93,000. Walleye Capital LLC bought a new stake in Kestra Medical Technologies in the second quarter worth about $166,000. Rhumbline Advisers bought a new stake in Kestra Medical Technologies in the second quarter worth about $200,000. JPMorgan Chase & Co. bought a new stake in Kestra Medical Technologies in the second quarter worth about $256,000. Finally, Armistice Capital LLC raised its position in Kestra Medical Technologies by 82.7% in the second quarter. Armistice Capital LLC now owns 22,834 shares of the company's stock worth $379,000 after acquiring an additional 10,334 shares during the period.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company decreased their price target on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Kestra Medical Technologies presently has an average rating of "Moderate Buy" and an average price target of $27.33.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.